10
Feb

Right on schedule, Gilead has submitted for FDA approval for its combination hepatitis C treatment, inching toward the era of interferon-free treatment and widening its lead on rival AbbVie.

…read more

Source: Gilead hands its hep C combo to the FDA as AbbVie race heats up

    

0 No comments